• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.应用基于生理学的药代动力学模型进行公共卫生决策面临的挑战。
Toxicol Sci. 2018 Apr 1;162(2):341-348. doi: 10.1093/toxsci/kfy010.
2
PBPK model reporting template for chemical risk assessment applications.用于化学风险评估应用的 PBPK 模型报告模板。
Regul Toxicol Pharmacol. 2020 Aug;115:104691. doi: 10.1016/j.yrtph.2020.104691. Epub 2020 Jun 2.
3
Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.用于毒理学和风险评估的基于生理的药代动力学和基于生理的药效学模型的开发。
Toxicol Lett. 1995 Sep;79(1-3):35-44. doi: 10.1016/0378-4274(95)03355-o.
4
Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.基准剂量和药代动力学模型在非癌症风险评估中的潜在影响研究。
J Toxicol Environ Health. 1997 Dec 26;52(6):475-515. doi: 10.1080/00984109708984077.
5
A framework for application of quantitative property-property relationships (QPPRs) in physiologically based pharmacokinetic (PBPK) models for high-throughput prediction of internal dose of inhaled organic chemicals.用于高通量预测吸入有机化学品体内剂量的生理相关药代动力学 (PBPK) 模型中定量性质-性质关系 (QPPR) 应用的框架。
Chemosphere. 2019 Jan;215:634-646. doi: 10.1016/j.chemosphere.2018.10.041. Epub 2018 Oct 8.
6
Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.基于生理学的药代动力学-定量系统毒理学和安全性 (PBPK-QSTS) 建模方法应用于预测阿米替林在人群和个体中的药代动力学变异性和心脏安全性。
J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):663-677. doi: 10.1007/s10928-018-9597-6. Epub 2018 Jun 25.
7
Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency.在欧洲药品管理局的监管决策中应用基于生理学的药代动力学建模。
Clin Pharmacol Ther. 2017 Jul;102(1):98-105. doi: 10.1002/cpt.539. Epub 2016 Dec 26.
8
Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough.基于生理学的药代动力学模型在风险评估中的应用——仅仅发表是不够的。
Toxicol Sci. 2012 Mar;126(1):5-15. doi: 10.1093/toxsci/kfr295. Epub 2011 Nov 1.
9
Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.基于生理药代动力学模型的模拟应用于监管决策及其对美国处方信息的影响:美国 FDA 临床药理学办公室 2018-2019 年提交文件的更新。
J Clin Pharmacol. 2020 Oct;60 Suppl 1:S160-S178. doi: 10.1002/jcph.1767.
10
Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.基于生理的药代动力学建模:方法、应用及局限性,重点关注其在儿科药物研发中的作用
J Biomed Biotechnol. 2011;2011:907461. doi: 10.1155/2011/907461. Epub 2011 Jun 1.

引用本文的文献

1
Assessing the Application of Physiologically Based Pharmacokinetic Models in Acute Chemical Incidents.评估基于生理的药代动力学模型在急性化学事故中的应用。
J Xenobiot. 2025 Mar 11;15(2):42. doi: 10.3390/jox15020042.
2
The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.药物计量学在推进自身免疫性疾病治疗中的作用。
Pharmaceutics. 2024 Dec 5;16(12):1559. doi: 10.3390/pharmaceutics16121559.
3
Pharmacokinetic Simulation and Area under the Curve Estimation of Drugs Subject to Enterohepatic Circulation.肠肝循环药物的药代动力学模拟及曲线下面积估计
Pharmaceutics. 2024 Aug 6;16(8):1044. doi: 10.3390/pharmaceutics16081044.
4
Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics.抗病毒药物和疫苗在孕妇中的安全性与有效性:基于生理的药代动力学建模及病毒感染动力学整合的见解
Vaccines (Basel). 2024 Jul 16;12(7):782. doi: 10.3390/vaccines12070782.
5
A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against .一种基于生理学的药代动力学/药效学模型,用于确定阿地普明的给药方案和停药间隔时间 。 (原文最后“against.”后面内容缺失,翻译到此为止)
Front Pharmacol. 2024 Apr 17;15:1378034. doi: 10.3389/fphar.2024.1378034. eCollection 2024.
6
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.推进精准医学:药物研发、临床药理学和个性化医疗中创新的计算机模拟方法综述。
Pharmaceutics. 2024 Feb 27;16(3):332. doi: 10.3390/pharmaceutics16030332.
7
Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding.基于生理的放射性药物动力学(PBRPK)建模以模拟和分析放射性药物治疗:非线性、多次推注注射及白蛋白结合的研究
EJNMMI Radiopharm Chem. 2024 Jan 22;9(1):6. doi: 10.1186/s41181-023-00236-w.
8
A science-based agenda for health-protective chemical assessments and decisions: overview and consensus statement.基于科学的健康保护化学评估和决策议程:概述和共识声明。
Environ Health. 2023 Jan 12;21(Suppl 1):132. doi: 10.1186/s12940-022-00930-3.
9
Machine Learning and Artificial Intelligence in Toxicological Sciences.机器学习和人工智能在毒理学科学中的应用。
Toxicol Sci. 2022 Aug 25;189(1):7-19. doi: 10.1093/toxsci/kfac075.
10
An Interactive Generic Physiologically Based Pharmacokinetic (igPBPK) Modeling Platform to Predict Drug Withdrawal Intervals in Cattle and Swine: A Case Study on Flunixin, Florfenicol, and Penicillin G.一种交互式通用生理药代动力学(igPBPK)建模平台,用于预测牛和猪的停药期:以氟尼辛、氟苯尼考和青霉素 G 为例。
Toxicol Sci. 2022 Jul 28;188(2):180-197. doi: 10.1093/toxsci/kfac056.

本文引用的文献

1
Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.研究基于生理学的动力学建模实践的现状,以及与获得模型应用的监管部门认可相关的挑战。
Regul Toxicol Pharmacol. 2017 Nov;90:104-115. doi: 10.1016/j.yrtph.2017.08.019. Epub 2017 Sep 1.
2
Physiologically based pharmacokinetic modeling of human exposure to perfluorooctanoic acid suggests historical non drinking-water exposures are important for predicting current serum concentrations.基于生理的人体全氟辛酸暴露药代动力学模型表明,历史上非饮用水暴露对于预测当前血清浓度很重要。
Toxicol Appl Pharmacol. 2017 Sep 1;330:9-21. doi: 10.1016/j.taap.2017.07.001. Epub 2017 Jul 3.
3
A global human health risk assessment for octamethylcyclotetrasiloxane (D).八甲基环四硅氧烷(D)的全球人类健康风险评估。
Toxicol Lett. 2017 Oct 20;279 Suppl 1:23-41. doi: 10.1016/j.toxlet.2017.05.019. Epub 2017 May 15.
4
Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.一种结合体外生理药代动力学(PBK)和蒙特卡洛模拟方法的开发,用于预测苯酚诱导的发育毒性中的个体间人类差异。
Toxicol Sci. 2017 Jun 1;157(2):365-376. doi: 10.1093/toxsci/kfx054.
5
Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver.结合转录组学和生理药代动力学(PBPK)模型表明,缺氧和昼夜节律信号改变在二氯甲烷对小鼠肺和肝脏致癌性中起主要作用。
Toxicol Appl Pharmacol. 2017 Oct 1;332:149-158. doi: 10.1016/j.taap.2017.04.002. Epub 2017 Apr 7.
6
A tissue dose-based comparative exposure assessment of manganese using physiologically based pharmacokinetic modeling-The importance of homeostatic control for an essential metal.使用基于生理的药代动力学模型对锰进行基于组织剂量的比较暴露评估——稳态控制对必需金属的重要性。
Toxicol Appl Pharmacol. 2017 May 1;322:27-40. doi: 10.1016/j.taap.2017.02.015. Epub 2017 Feb 22.
7
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.生理药代动力学模型中的应用概念:如何构建生理药代动力学/药效学模型。
CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19.
8
Modeling Pharmacokinetics.药代动力学建模
Methods Mol Biol. 2016;1425:37-62. doi: 10.1007/978-1-4939-3609-0_3.
9
Multiscale modelling approaches for assessing cosmetic ingredients safety.用于评估化妆品成分安全性的多尺度建模方法。
Toxicology. 2017 Dec 1;392:130-139. doi: 10.1016/j.tox.2016.05.026. Epub 2016 Jun 4.
10
Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards.将基于生理的生命阶段药代动力学模型与不良结局途径及环境暴露模型相结合以筛选环境危害
Toxicol Sci. 2016 Jul;152(1):230-43. doi: 10.1093/toxsci/kfw082. Epub 2016 May 4.

应用基于生理学的药代动力学模型进行公共卫生决策面临的挑战。

Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.

机构信息

National Exposure Research Laboratory, United States Environmental Protection Agency, Research Triangle Park, North Carolina 27709.

Agency for Toxic Substances and Disease Registry, Atlanta, Georgia 30341.

出版信息

Toxicol Sci. 2018 Apr 1;162(2):341-348. doi: 10.1093/toxsci/kfy010.

DOI:10.1093/toxsci/kfy010
PMID:29385573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6084449/
Abstract

The development and application of physiologically based pharmacokinetic (PBPK) models in chemical toxicology have grown steadily since their emergence in the 1980s. However, critical evaluation of PBPK models to support public health decision-making across federal agencies has thus far occurred for only a few environmental chemicals. In order to encourage decision-makers to embrace the critical role of PBPK modeling in risk assessment, several important challenges require immediate attention from the modeling community. The objective of this contemporary review is to highlight 3 of these challenges, including: (1) difficulties in recruiting peer reviewers with appropriate modeling expertise and experience; (2) lack of confidence in PBPK models for which no tissue/plasma concentration data exist for model evaluation; and (3) lack of transferability across modeling platforms. Several recommendations for addressing these 3 issues are provided to initiate dialog among members of the PBPK modeling community, as these issues must be overcome for the field of PBPK modeling to advance and for PBPK models to be more routinely applied in support of public health decision-making.

摘要

自 20 世纪 80 年代以来,生理药代动力学(PBPK)模型在毒理学中的发展和应用稳步增长。然而,到目前为止,只有少数环境化学物质对支持联邦机构公共卫生决策的 PBPK 模型进行了关键性评估。为了鼓励决策者在风险评估中接受 PBPK 建模的关键作用,建模界需要立即关注几个重要挑战。本综述的目的是强调其中的 3 个挑战,包括:(1)难以招募具有适当建模专业知识和经验的同行评审员;(2)对于没有组织/血浆浓度数据可用于模型评估的 PBPK 模型缺乏信心;以及(3)跨建模平台的可转移性缺乏。为了解决这 3 个问题,提出了一些建议,以便在 PBPK 建模界成员之间展开对话,因为必须克服这些问题,PBPK 建模领域才能取得进展,PBPK 模型才能更常规地应用于支持公共卫生决策。